StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Scribe Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Scribe Therapeutics's enterprise value was -$1.10M on Nov 11, 2026.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$1.10M–

More Scribe Therapeutics figures

See a number that looks wrong?